Last reviewed · How we verify
STX209
At a glance
| Generic name | STX209 |
|---|---|
| Also known as | arbaclofen |
| Sponsor | Seaside Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion (PHASE2)
- Arbaclofen in Children and Adolescents With ASD (PHASE2)
- Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD) (NA)
- MEG Study of Acute STX209 Effects in ASD (EARLY_PHASE1)
- Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (PHASE3)
- Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders (PHASE3)
- Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (PHASE3)
- An Open Label Extension Study in Subjects With Fragile X Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STX209 CI brief — competitive landscape report
- STX209 updates RSS · CI watch RSS
- Seaside Therapeutics, Inc. portfolio CI